aripiprazole has been researched along with Cardiovascular Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Edelsohn, GA | 1 |
| Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
| Andrade, C | 1 |
| Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R | 1 |
| Coffey, DB; John, N; Potter, PO | 1 |
| Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
1 review(s) available for aripiprazole and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Fructose; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Schizophrenia; Topiramate | 2016 |
1 trial(s) available for aripiprazole and Cardiovascular Diseases
| Article | Year |
|---|---|
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2011 |
4 other study(ies) available for aripiprazole and Cardiovascular Diseases
| Article | Year |
|---|---|
Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Child; Clinical Decision-Making; Diabetes Mellitus, Type 2; Humans; Psychotic Disorders; Quetiapine Fumarate | 2019 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
Topics: Adrenergic alpha-Agonists; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Asthma; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Chest Pain; Child; Dyskinesia, Drug-Induced; Family; Female; Guanfacine; Humans; Lithium Chloride; Male; Mood Disorders; Neuropsychological Tests; Obesity; Paroxetine; Piperazines; Polypharmacy; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Agitation; Quinolones; Selective Serotonin Reuptake Inhibitors; Smoking; Social Environment | 2012 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |